Mabpharm Limited (HK:2181)
:2181
Want to see HK:2181 full AI Analyst Report?
2181 Stock Chart & Stats
HK$0.50
>-HK$0.01(-1.85%)
At close: 4:00 PM EST
HK$0.50
>-HK$0.01(-1.85%)
Day’s Range― - ―
52-Week RangeHK$0.40 - HK$0.88
Previous CloseN/A
Volume6.00K
Average Volume (3M)354.33K
Market Cap
HK$1.77B
Enterprise ValueHK$1.62B
Total Cash (Recent Filing)HK$109.30M
Total Debt (Recent Filing)HK$326.88M
Price to Earnings (P/E)26.6
Beta0.98
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding4,124,080,000
10 Day Avg. Volume54,400
30 Day Avg. Volume354,333
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)11.77
Price to Sales (P/S)2.94
P/FCF Ratio-79.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue TurnaroundA sharp 2025 revenue increase (+48.5%) and a return to positive net income (~8.8% net margin) indicate meaningful demand recovery and improved unit economics. Over a 2–6 month horizon this supports scalable revenue capture, better operating leverage, and stronger ability to fund growth or deleveraging if sustained.
High Gross MarginsVery high gross margins (72%–86%) reflect strong product economics and likely pricing power or low variable costs. Structurally this provides a durable buffer to absorb SG&A or R&D spend while still generating gross profit, supporting long-term margin resilience if fixed costs are controlled.
Positive Operating Cash FlowPositive operating cash flow (~80.8M in 2025) shows the core business can generate cash from operations. Over months this improves the firm's ability to fund working capital and investments internally, reduces near-term financing reliance, and offers a pathway to stabilize balance-sheet risk if cash generation remains consistent.
Bears Say
Elevated LeverageHigh leverage (debt-to-equity ~2.08 after ~3.30) means a small equity base finances a large portion of assets. This reduces financial flexibility, raises interest and refinancing risk, and amplifies earnings volatility; if cash flow weakens, debt service obligations could constrain strategic decisions and solvency over months.
Negative Free Cash FlowNegative free cash flow (~-23.2M) despite positive net income signals weak cash conversion and ongoing investment or working-capital drain. Structurally this forces reliance on external financing or equity issuance to fund operations and growth, undermining sustainability of reported profits and limiting ability to de-lever without new capital.
Thin Operating ProfitabilityA very slim EBIT margin (~0.7%) shows operating profits are fragile despite healthy gross margins. This exposes the business to margin erosion from modest cost increases or slower revenue growth, limiting the company’s ability to invest in commercialization or R&D while preserving durable profitability over the medium term.
Mabpharm Limited News
2181 FAQ
What was Mabpharm Limited’s price range in the past 12 months?
Mabpharm Limited lowest stock price was HK$0.40 and its highest was HK$0.88 in the past 12 months.
What is Mabpharm Limited’s market cap?
Mabpharm Limited’s market cap is HK$1.77B.
When is Mabpharm Limited’s upcoming earnings report date?
Mabpharm Limited’s upcoming earnings report date is Aug 21, 2026 which is in 77 days.
How were Mabpharm Limited’s earnings last quarter?
Mabpharm Limited released its earnings results on Mar 26, 2026. The company reported HK$0.014 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.014.
Is Mabpharm Limited overvalued?
According to Wall Street analysts Mabpharm Limited’s price is currently Overvalued.
Does Mabpharm Limited pay dividends?
Mabpharm Limited does not currently pay dividends.
What is Mabpharm Limited’s EPS estimate?
Mabpharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabpharm Limited have?
Mabpharm Limited has 4,124,080,000 shares outstanding.
What happened to Mabpharm Limited’s price movement after its last earnings report?
Mabpharm Limited reported an EPS of HK$0.014 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mabpharm Limited?
Currently, no hedge funds are holding shares in HK:2181
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mabpharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.77%
12-Months-Change
Fundamentals
Return on Equity
43.89%
Trailing 12-Months
Asset Growth
18.80%
Trailing 12-Months
Company Description
Mabpharm Limited
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer. In addition, its products under the pre-clinical stage include CMAB810 for the treatment of breast cancer; CMAB816 for the treatment of periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; CMAB017 for the treatment of KRAS wild-type colorectal cancer; CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; and CMAB022 for the treatment of inflammatory diseases. The company also involved in research and development, technical consulting, technology transfer, and technical services of biological products, diagnostic reagents, chemical biological reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, the People's Republic of China.
Technical Analysis
Alphamab Oncology
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
SinoMab Bioscience Ltd.
―